Relay Therapeutics

More: ir.relaytx.com/news-releases/…

We're pleased to share Ph1/2 data from the ReDiscover trial at the 400mg BID fed dose of zovegalisib+fulvestrant in patients w/ PI3Kα-mutated, HR+/HER2- metastatic #breastcancer at ESMO TAT, supporting our decision to advance this regimen into the ongoing Ph3 ReDiscover-2 trial.

We were on the ground at #MBCC26 & were grateful for the opportunity to connect with investigators, research partners, & the #breastcancer community as we continue advancing innovative therapies for patients. Thanks to all who joined for our ReDiscover and ReDiscover-2 posters.

We were pleased to host BOD member Linda Hill & her coauthor Emily Tedards, as part of a tour for their new book “Genius at Scale.” They shared insights on building innovative companies by creating trust, encouraging bold ideas & fostering collaboration. Thank you Linda & Emily!

Today, we are pleased to report fourth quarter and full year 2025 financial results along with anticipated 2026 milestones. Listen below as CEO @SanjivKPatel1 shares more about the year ahead. Full details here. ir.relaytx.com/news-releases/…

Ahead of #RareDiseaseDay, we gathered to better understand rare diseases & experiences of those living with them. As we advance our research in vascular anomalies & Fabry disease, we are today reminded of the unmet need in rare diseases & reinforce our commitment to patients.

Relay Tx was excited to join the kickoff session for the @CLOVESSyndrome International CLOVES Summit. As the event sponsor, we're grateful to participate in an event that will bring together patients, families, and researchers. Learn more about the summit: clovessyndrome.org/current-event/…

We will present initial Phase 1/2 data of zovegalisib plus fulvestrant at the 400mg BID fed dose (the Phase 3 dose) in CDK4/6-experienced patients this March at #ESMOTAT26. Details here: ir.relaytx.com/news-releases/…

Today, we announced that the US FDA has granted zovegalisib Breakthrough Therapy Designation for PIK3CA-mutant, HR+/HER2- advanced #breastcancer, supported by data from our ReDiscover trial testing zovegalisib at the 600mg BID fasted & 400mg BID fed doses in combo w/ fulvestrant.

Santa only puts in one long shift. Relayers put in a full year of dedication. 2025 was a busy one and now it’s time to slow down, recharge, and celebrate with family, friends, and our little pastry chefs!

Today at #SABCS25, we are pleased to announce an efficacy subset analysis of zovegalisib (RLY-2608) + fulvestrant from the Phase 1/2 ReDiscover trial in PI3Kα-mutated, metastatic #breastcancer patients. Learn more here. ir.relaytx.com/news-releases/…

Join us at #SABCS25 this week! We look forward to sharing the latest updates from our ongoing #breastcancer clinical trials this Friday. More details below.

Before Relayers brave the Thanksgiving traffic 🚗 Before we soak the turkey in a brine 🦃 Employees soaked in the spirit of gratitude, writing handwritten thank notes to colleagues across the organization 📨 Who doesn't like getting mail!? 📬 Happy Thanksgiving!

Congratulations to @EuropaDonna’s 17th Pan European Conference for once again bringing leaders and patients together from across Europe to advocate for advances in breast cancer care.

Caregivers play an essential role for people facing health challenges. Their needs are often overlooked, placing a hidden burden on families. We recognize the efforts of all caregivers & acknowledge that support for them is critical. #NationalFamilyCaregiversMonth

It was a fantastic 3 days for our team in Lisbon at @ABCGlobalAll! Patient advocacy leaders and providers from around the world met to share insights, collaborate, and evaluate emerging treatments in order to shape what comes next for advanced and metastatic breast cancer!

We're excited to announce the appointment of Lonnel Coats & Habib Dable to our Board of Directors. As former biotech CEOs, Lonnel & Habib have decades of launch & commercialization expertise to offer. Read more in today's Q3 earnings: ir.relaytx.com/news-releases/…

Join our partner @SusanGKomen for Breast Cancer Breakthroughs! The PI3K pathway can play a key role in some types of breast cancer. Watch here about the challenges of targeting this pathway & how new research is ushering in new ways to treat breast cancer: bit.ly/3X1yPW0

We held an educational webinar on our PIK3CA-driven #vascularmalformations program. We value opportunities to raise awareness of this underserved space & are committed to advancing research aimed at helping address unmet needs in VMs. Learn more: relaytx.com/pipeline/

Relayers recently hit the streets for a scavenger hunt. The very streets where Julia Child once shopped for groceries, the Affleck/Damon duo wrote "Good Will Hunting," & where the world's most exciting science is happening. We're proud to be a part of Cambridge biotech history!